Furthermore, modified heparin derivatives demonstrate potential in blocking galectin 3-mediated cancer cell adhesion and angiogenesis, offering a new frontier in anti-metastasis and anti-cancer drug development [181]. The gene discussed is LGALS3; the disease is cancer.